Doctor Felix Hofer

Medical University of Vienna, Vienna (Austria)

Contributor content

$Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction$

Presentation

Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction

Presentation

Fibroblast growth factor-23 is an independent predictor of hospitalization for heart failure and major cardiovascular adverse events in patients undergoing cardiac surgery

Presentation

Influence of diabetes, heart failure, and NT-proBNP on cardiovascular outcomes in patients with atrial fibrillation - Insights from a cohort study of 7,412 patients with extended follow-up

Presentation

The prognostic impact of fibroblast growth factor-23 on cardiovascular death after cardiac surgery

Presentation

Prognostic impact of left ventricular thrombus resolution after myocardial infarction on cardiovascular events and mortality

Explore sponsored resources

Doctor Felix Hofer

Contributor content

Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction

Fibroblast growth factor-23 is an independent predictor of hospitalization for heart failure and major cardiovascular adverse events in patients undergoing cardiac surgery

Influence of diabetes, heart failure, and NT-proBNP on cardiovascular outcomes in patients with atrial fibrillation - Insights from a cohort study of 7,412 patients with extended follow-up

The prognostic impact of fibroblast growth factor-23 on cardiovascular death after cardiac surgery

Prognostic impact of left ventricular thrombus resolution after myocardial infarction on cardiovascular events and mortality

ESC 365 is supported by